Unknown Primary Cancer of the Neck: Diagnosis and Treatment

When a patient comes to me with a lump in the neck, my first job is to figure out where it came from. Most of the time, we find the answer quickly — a lymph node enlarged from a known primary tumor in the mouth, throat, or thyroid. But occasionally, even after thorough testing and examination, we cannot find the original source. This is called unknown primary cancer of the neck, or carcinoma of unknown primary (CUP). It is one of the more diagnostically challenging situations in head and neck oncology, and it requires a specific, systematic approach to treat effectively.

What Does "Unknown Primary" Mean?

When cancer spreads to a lymph node in the neck, it typically originates from a tumor somewhere in the head and neck region — the base of tongue, tonsils, larynx, hypopharynx, or another mucosal site. In most cases, that primary tumor is visible on exam or imaging. In unknown primary cancer, however, the metastatic lymph node is found first, and the source tumor is either too small to detect, located in an area that is difficult to visualize, or in rare cases never found at all.

This is not simply a matter of doing more scans. Squamous cell carcinoma, the most common cancer found in these neck nodes, can hide in the deep crypts of tonsillar tissue or at the base of the tongue — areas where even a skilled examiner can miss a small lesion without specialized tools. HPV-positive tumors in particular are notorious for presenting as a bulky neck mass while the primary in the throat remains tiny and occult.

The distinction matters because treatment strategy depends substantially on knowing — or not knowing — where the cancer originated. When the primary is unknown, we must plan treatment to cover the likely sites of origin, which influences the extent of surgery, radiation fields, and overall prognosis.

How the Workup Is Done

The evaluation of a neck mass suspicious for unknown primary cancer is systematic and deliberate. It begins with a detailed history and physical examination, including a thorough inspection of the entire head and neck mucosa. I use fiberoptic transnasal endoscopy in the office to examine areas not visible to the naked eye — the nasopharynx, oropharynx, hypopharynx, and larynx.

Imaging is critical. CT neck with contrast reveals anatomic details and often can show subtle patterns indicating a small primary focus. A PET-CT scan is a valuable study because it maps metabolic activity throughout the body and can reveal both the primary site and any other areas of metastatic disease. An MRI of the neck is occasionally complementary for the soft tissue detail, particularly for the base of tongue and tonsillar region. Together, these studies identify a primary site in many patients who initially appeared to have unknown primary disease.

Molecular testing adds another layer. HPV and EBV status of the metastatic lymph node is routinely obtained, because these markers strongly suggest the anatomic origin. An HPV-positive lymph node almost always points to an oropharyngeal primary, even if that primary cannot be found. EBV positivity in a cervical node directs evaluation toward the nasopharynx. This information shapes both the diagnostic evaluation and the treatment approach even when the primary tumor itself remains elusive.

If imaging does not reveal a primary, the next step is examination under anesthesia. In the operating room, I perform a panendoscopy — a comprehensive inspection of the entire upper aerodigestive tract using rigid and flexible telescopes — combined with targeted biopsies of the most likely primary sites. This includes biopsies of the base of tongue, nasopharynx, and sampling of any mucosal abnormality, and also tonsillectomies. It is not uncommon for a small HPV-positive tumor to be found within a tonsillar biopsy that was imperceptible on imaging or clinical exam.

Treatment Options and How Decisions Are Made

Unknown primary head and neck cancer is treated with curative intent. The prognosis, particularly for HPV-positive disease, is often favorable — comparable in many cases to known HPV-positive oropharyngeal cancers. The challenge is designing a treatment plan that covers all likely primary sites without unnecessarily treating the entire head and neck.

Treatment decisions are made at our weekly multidisciplinary tumor board, where I review cases with medical oncology, radiation oncology, pathology, and radiology together. For unknown primary cancer, the key question is whether surgery, radiation, chemotherapy, or some combination offers the best outcome with acceptable morbidity.

Surgery plays a role in several ways. Neck dissection — surgical removal of the lymph nodes in the neck — is often recommended as part of treatment, both to control regional disease and to obtain detailed pathologic information about the extent of nodal involvement. If a primary site is identified at the time of operative evaluation (through tonsillectomy or directed biopsy), it may be resected at the same time. Transoral robotic surgery (TORS) has expanded the ability to perform minimally invasive resections of the base of tongue and tonsillar tissue. For many patients, I prefer a TORS-based tonsillectomy and resection approach allows detection and resection of a previously unidentified primary, in combination with a neck dissection, to completely treat the disease.

Radiation therapy is often part of the treatment plan. The extent of the radiation field is a nuanced decision: treating only the known nodal disease minimizes side effects but risks missing an undetected primary; treating a broader field that includes likely primary sites (bilateral tonsils, base of tongue, nasopharynx) is more comprehensive but carries greater toxicity. This is an area of active research, and for HPV-positive patients with favorable disease, de-escalated approaches are increasingly being explored.

Chemotherapy is frequently added when there are high-risk features in the neck — particularly extranodal extension, meaning cancer that has grown through the wall of the lymph node into surrounding tissue. Concurrent platinum-based chemotherapy with radiation is the standard in these situations.

What Patients Should Know About Prognosis

One of the most important things I communicate to patients with unknown primary cancer is that this diagnosis, while alarming in its ambiguity, does not automatically carry a poor prognosis. For patients with HPV-positive disease — which represents the majority of unknown primary squamous cell carcinomas in the neck today — outcomes are genuinely encouraging. Multiple studies have shown five-year survival rates that rival or exceed those of known HPV-positive oropharyngeal cancer, likely because the primary tumor is often small and the disease biology is favorable.

For HPV-negative unknown primary cancer, outcomes are more variable and depend heavily on the stage and extent of nodal disease. These patients require the same comprehensive, multidisciplinary approach, often with more aggressive treatment fields.

Uncertainty is hard. Not knowing exactly where the cancer started is a source of real psychological distress for patients, who naturally want a clear answer. I try to be honest: in some cases, after exhaustive evaluation, we never find the primary — and that is not necessarily a failure of diagnosis. What matters is that the disease is treated comprehensively and that ongoing surveillance is maintained. Regular follow-up exams and periodic imaging ensure that if a primary site eventually becomes apparent, it is identified and addressed promptly.

Next Steps

If you have been told there is a mass or abnormal lymph node in your neck, particularly if a biopsy has shown cancer cells without a clear source, I encourage you to seek evaluation at a high-volume head and neck cancer center. The workup for unknown primary cancer requires coordination between surgery, diagnostic radiology, pathology, and radiation oncology — and the treatment plan must be built around your specific disease characteristics.

I see patients with unknown primary cancer of the neck regularly and approach each case with the same thorough evaluation and multidisciplinary planning. If you have questions or would like a consultation, call 414-649-3920 to schedule an appointment.

Dr. Steven Sperry is a fellowship-trained head and neck surgeon specializing in head and neck cancer surgery and microvascular free flap reconstruction at Aurora St. Luke's Medical Center in Milwaukee, Wisconsin.